We fund the development of innovative tools and technologies to accelerate the discovery and development of safer and more effective drugs.
0
FUNDED PROJECTS
0
RESEARCH INSTITUTIONS
0
MILLION $ INVESTED IN R&D
0
MILLION $ IN CO-FINANCING
0
MILLION $ IN FOLLOW-ON INVESTMENTS
Our Programs
Quantum Leap
CQDM supports precompetitive research involving technological breakthroughs that will boost the productivity of biopharmaceutical R&D while meeting critical unmet needs of the industry.
Quantum Leap
Call for Proposals
March 27, 2019
SynergiQc
With the SynergiQc program, CQDM expands its reach to promote research initiatives between the industry and academia that will generate economic benefits for Quebec.
SynergiQc
Call for Proposals
April 17, 2019
Mentorship
This program successfully builds dynamic partnerships, matching researchers funded by CQDM with influential senior scientists from CQDM’s global pharma members.
Mentorship
A win-win
collaboration
Latest news
Contact us
740, Notre-Dame St, suite 1400
Montreal (Quebec) H3C 3X6, Canada
Phone: 514 766-6661
Fax: 514 766-9613
Email: info@cqdm.org
GOVERNMENT SPONSORS
Business-Led Networks of Centres of Excellence
This program is administered by the Networks of Centres of Excellence (NCE) Secretariat. Launched in 1989, the NCE is an initiative of the three federal granting agencies—the Natural Sciences and Engineering Research Council of Canada (NSERC), the Social Sciences and Humanities Research Council of Canada (SSHRC) and the Canadian Institutes for Health Research (CIHR)—in partnership with Industry Canada.
The Business-Led Networks of Centres of Excellence program supports large-scale, collaborative research networks. BL-Networks aim at enhancing private sector innovation, delivering benefits to Canadians and encouraging an Entrepreneurial Advantage.”
The mission of the Ministère de l’Économie et de l’Innovation (MEI) is to support business growth, entrepreneurship, science, innovation, export trade and investment. It also advises the Government with a view to favouring economic development in every region of Québec, in a perspective of job creation, economic prosperity, and sustainable development.
FOUNDING PARTNERS
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines and vaccines. Every day, Pfizer Canada employees work to bring therapies to patients that significantly improve their lives. The company is a major contributor to health research in Canada. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything Pfizer does, from our disease awareness initiatives to our community partnerships, to our belief that it takes more than medications to be truly healthy. To learn more about Pfizer’s More than Medication philosophy and programs, visit www.morethanmedication.ca.
MEMBERS INVOLVED IN PROGRAM FUNDING
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability. In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
GlaxoSmithKline Inc. (GSK) is a research-based pharmaceutical company with a challenging mission: to improve the quality of people's lives by enabling them to do more, feel better and live longer. This mission drives GSK to develop innovative medicines, vaccines and healthcare solutions that help millions of people.
The goal of this website is to provide Canadian Healthcare Professionals, patients and members of the public with comprehensive information on our medications.
Janssen Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which are dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world.
www.janssen.ca
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, a man committed to creating high quality medicines that meet people’s needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism. Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world’s first commercially-available insulin. Lilly Canada now employs more than 550 people across the country, working in the areas of oncology, cardiovascular and endocrine disorders, men’s and women’s health, autoimmunity, neuroscience and diabetes.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2013, the company invested close to $100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi entities in Canada include Sanofi Canada (pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health (cosmeceuticals, over-the-counter products and specialty care), Genzyme (rare diseases) and Merial (animal health). Together they employ close to 1,700 people across the country. In 2013 Sanofi companies invested over $125 million in R&D in Canada, creating jobs, business and opportunity throughout the country.
Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier Canada was established in 1978 in Laval, Quebec and employs over 320 people across Canada. Servier Canada is currently marketing medicines in Cardiology, Hematology and Diabetes, and will soon market oncology products indicated as treatment options in hematological malignancies.
